A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Paediatric Patients With Alagille Syndrome

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Paediatric Patients With Alagille Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Lopixibat chloride (Primary)
  • Indications Alagille syndrome
  • Focus Therapeutic Use
  • Acronyms IMAGO
  • Sponsors Lumena Pharmaceuticals
  • Most Recent Events

    • 09 Apr 2015 Topline results published in the Shire media release.
    • 09 Apr 2015 Primary endpoint has not been met, according to Shire media release.
    • 18 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top